Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 4
2018 1
2019 1
2020 1
2021 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Dietz J, et al. J Hepatol. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19. J Hepatol. 2021. PMID: 33220331
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Di Maio VC, et al. Among authors: barbaliscia s. Liver Int. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8. Liver Int. 2021. PMID: 33497016
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Di Maio VC, et al. Among authors: barbaliscia s. J Hepatol. 2018 Mar;68(3):597-600. doi: 10.1016/j.jhep.2017.09.008. Epub 2017 Sep 20. J Hepatol. 2018. PMID: 28939133 No abstract available.
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b.
Alkhatib M, Di Maio VC, De Murtas V, Polilli E, Milana M, Teti E, Fiorentino G, Calvaruso V, Barbaliscia S, Bertoli A, Scutari R, Carioti L, Cento V, Santoro MM, Orro A, Maida I, Lenci I, Sarmati L, Craxì A, Pasquazzi C, Parruti G, Babudieri S, Milanesi L, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F, Svicher V, Salpini R, On Behalf Of Hirma Hepatocarcinoma Innovative Research MArkers And Fondazione Vironet C Hcv Virology Italian Resistance. Alkhatib M, et al. Among authors: barbaliscia s. Viruses. 2021 Apr 23;13(5):743. doi: 10.3390/v13050743. Viruses. 2021. PMID: 33922732 Free PMC article.
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.
Cento V, Aragri M, Teti E, Polilli E, Bertoli A, Foroghi L, Barbaliscia S, Di Maio VC, Pieri A, Pace Palitti V, Sarmati L, Parruti G, Andreoni M, Perno CF, Ceccherini-Silberstein F. Cento V, et al. Among authors: barbaliscia s. J Antimicrob Chemother. 2017 Dec 1;72(12):3420-3424. doi: 10.1093/jac/dkx302. J Antimicrob Chemother. 2017. PMID: 28961921 Free article.
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Rossetti B, Paglicci L, Di Maio VC, Cassol C, Barbaliscia S, Paolucci S, Bruzzone B, Coppola N, Montagnani F, Micheli V, Monno L, Zanelli G, Santantonio T, Cuomo N, Caudai C, Zazzi M, Ceccherini-Silberstein F, On Behalf Of The Hcv Virology Italian Resistance Network Vironet C. Rossetti B, et al. Among authors: barbaliscia s. Infez Med. 2021 Jun 1;29(2):242-251. Infez Med. 2021. PMID: 34061790 Free article.
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients.
Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. Bellocchi MC, et al. Among authors: barbaliscia s. Cells. 2019 Jul 2;8(7):666. doi: 10.3390/cells8070666. Cells. 2019. PMID: 31269695 Free PMC article.
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Di Maio VC, et al. Among authors: barbaliscia s. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. Liver Int. 2017. PMID: 28105744
11 results